Aberdeen Group plc Trims Stock Holdings in Quanterix Corporation $QTRX

Key Points

• Aberdeen Group plc cut its stake in Quanterix by 81.6% in Q4, selling 460,542 shares and retaining 104,039 shares worth about $662,000.
• Several other institutions sharply increased positions (notably Millennium Management’s +9,880.2% to ~1.21M shares) and overall institutional/hedge fund ownership stands at 86.48%.
• Quanterix trades near its 1‑year low (~$3.30) with a $155M market cap, reported a Q loss of $0.38 EPS (missing estimates) despite a revenue beat, and carries a consensus analyst stance of “Reduce” with an $8 target.

Aberdeen Group plc reduced its position in shares of Quanterix Corporation (NASDAQ:QTRX - Free Report) by 81.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 104,039 shares of the company's stock after selling 460,542 shares during the quarter. Aberdeen Group plc owned about 0.22% of Quanterix worth $662,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of QTRX. Millennium Management LLC increased its holdings in Quanterix by 9,880.2% during the 3rd quarter. Millennium Management LLC now owns 1,209,199 shares of the company's stock worth $6,566,000 after purchasing an additional 1,197,083 shares during the period. Balyasny Asset Management L.P. increased its holdings in Quanterix by 1,625.2% during the 2nd quarter. Balyasny Asset Management L.P. now owns 767,801 shares of the company's stock worth $5,106,000 after purchasing an additional 723,295 shares during the period. Portolan Capital Management LLC increased its holdings in Quanterix by 17.2% during the 3rd quarter. Portolan Capital Management LLC now owns 4,259,851 shares of the company's stock worth $23,131,000 after purchasing an additional 626,229 shares during the period. Ameriprise Financial Inc. increased its holdings in Quanterix by 14.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 4,236,877 shares of the company's stock worth $28,175,000 after purchasing an additional 521,639 shares during the period. Finally, Marshall Wace LLP bought a new stake in Quanterix during the 2nd quarter valued at $2,954,000. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Quanterix Price Performance

Quanterix stock opened at $3.30 on Friday. The business has a fifty day moving average price of $5.08 and a 200-day moving average price of $5.90. Quanterix Corporation has a 1-year low of $3.27 and a 1-year high of $8.77. The stock has a market capitalization of $154.90 million, a price-to-earnings ratio of -1.31 and a beta of 1.32.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.11). Quanterix had a negative return on equity of 23.96% and a negative net margin of 77.14%.The firm had revenue of $41.40 million for the quarter, compared to analyst estimates of $37.95 million. On average, equities research analysts anticipate that Quanterix Corporation will post -0.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on QTRX shares. Wall Street Zen raised Quanterix from a "sell" rating to a "hold" rating in a research report on Monday, December 29th. Canaccord Genuity Group increased their target price on Quanterix from $5.00 to $8.00 and gave the company a "hold" rating in a research report on Monday, December 22nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Quanterix in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Quanterix presently has a consensus rating of "Reduce" and a consensus target price of $8.00.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company's core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.

Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Corporation (NASDAQ:QTRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.